News

This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to the wider efforts of Johnson & Johnson

Ganetespib is a next-generation inhibitor of the chaperone protein Hsp90, which is critical for the activation and stability of numerous proteins that drive cancer growth and proliferation. Ganetespib

The multi-center, randomized, placebo-controlled, Phase IIb study, will be conducted primarily in the US and patient enrollment is expected to begin in the near future. The study is

The Phase Ib trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses of EPZ-5676 in patients between the ages of three months and 18

As part of the deal, Capricor has been granted an exclusive world-wide license, with the right to sublicense, IP related to exosomes originating from cardiosphere-derived cells (CDCs). The

The patent, which has terms that expire no earlier than 2031, covers the company’s unique formulation in conjunction with anti-obesity agents for the reduction of body weight in

The agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria, and etoricoxib is marketed under the brand name of Arcoxia in these markets. Grünenthal chief commercial officer

The agreement will allow the discovery and development of potential oral first-in-class compounds that inhibit Macrophage Migration Inhibitory Factor (MIF), a major regulatory cytokine that has been linked

The company announced the issuance of US Patent No. 8,701,658 entitled ‘Ventilation Circuit Adaptor and Proximal Aerosol Delivery System’ which provides coverage for our novel disposable aerosol airway